SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining traction within the crypto community, with discussions focusing on its cultural significance and potential. Community members are actively sharing links to the Weedcoin website and DEX Screener, while emphasizing the importance of embracing and preserving the "culture." The coin is presented as more than just a cryptocurrency, but rather a movement.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as the community rallies around its positive narrative and long-term vision, emphasizing conviction and community support. Bullish sentiment is fueled by the token's strong community and a belief that it's poised for significant growth, particularly within the Solana ecosystem. Discussions also highlight anticipation for potential listings and the project's alignment with broader crypto trends.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG is trending as the community celebrates its joke-inspired meme-coin status and continued presence on the Solana network. Active discussions revolve around the classic "What's Updog?" joke, with the community emphasizing its commitment and longevity in the crypto space, particularly its listing on Jupiter.

Valvoline, Inc. engages in the production, marketing, and supply of engine and automotive maintenance products and services. It operates through the Retail Services segment. The Retail Services segment services the passenger car and light truck quick lube market in the US and Canada with preventive maintenance services done through company operated and independent franchise care stores. The company was founded by John Ellis in 1866 and is headquartered in Lexington, KY.

Valvoline Inc

Valvoline is trending as community members discuss the company's potential for growth, driven by expansion plans including store openings and electric vehicle services. Some see it as a safe, long-term hold with the potential to test all-time highs. Bullish sentiment is fueled by analysis suggesting healthy financials and upcoming catalysts.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network is trending as the community anticipates the sunsetting of $PRQ, expecting it to remove arbitrage pressures and allow $REACT to trade more freely.  Enthusiasm is building around potential tier-1 exchange listings and the project's cross-chain smart contract technology, with some community members drawing comparisons to early-stage, high-potential cryptos. Bullish sentiment is fueled by recent integrations and partnerships, as well as a growing number of watchers.

Grayscale Ethereum Trust (ETH) operates as open-end investment company. Its investment objective is for the shares to reflect the value of ETH held by the trust. The company was founded on December 13, 2017 and is headquartered in Stamford, CT.

Grayscale Ethereum Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Ethereum Mini Trust

Grayscale Ethereum Mini Trust ($ETH) is trending amidst fluctuating market conditions, as the community discusses its potential and key support levels. Community members are closely watching for a breakout past all-time highs, fueled by institutional interest and potential rate cuts, while also debating its relationship with other cryptocurrencies and treasury plays. Recent news of large Ethereum purchases, BlackRock's activity, and regulatory developments are adding to the buzz.

$GRIPPY is the sticky meme frog of Base — goofy, wholesome, and powered by pure meme energy.   Inspired by Furie-style chaos and community culture, Grippy isn’t just another frog, he’s a sticky symbol of resilience, humor, and diamond-handed holding. Built with zero taxes, a renounced contract, and liquidity locked, $GRIPPY launched as a true fair-play meme coin for the people.  The project thrives on organic growth, viral campaigns, and community-driven governance. With staking pools, a Grippy Dashboard, and merch/NFT drops in the roadmap, $GRIPPY is here to stick as Base’s No. 1 meme.

GRIPPY

Grippy is trending as community members discuss its potential, low market cap, and availability on Coinbase. Speculation around upcoming listings on Bitmart and Pionex, along with a potential partnership, is fueling excitement. Comparisons to other meme coins like Doge and Shiba Inu are also circulating.

Hydrex is the MetaDEX & Liquidity Infrastructure purpose-built for Base. By combining automated strategies, liquid-backed tokenomics, and Base's powerful distribution channels, Hydrex removes the barriers to yield. It's designed as a coordination system where weekly community governance directs HYDX emissions & protocol revenue. Value flows to where liquidity and volume are most productive, based on protocol alignment.

Hydrex

Hydrex ($HYDX) is trending as a potential competitor to $AERO, with community members highlighting its recent launch on Base as a DUNA and locked tokenomics. Discussion centers on its potential for significant gains, driven by social media activity and comparisons to a larger market cap project, while some investors are drawn to its long-term potential.

Baby Doge Coin is a meme cryptocurrency designed to be deflationary and more scarce over time. All holders of Baby Doge will earn more baby doge that is automatically sent to your wallet by simply holding Baby Doge coins in your wallet. Watch the amount of baby doge grow in your wallet as baby doge coin holders automatically receive a 5% fee from every on chain transaction that happens on the Baby Doge ecosystem. The community receives more baby doge coins from the fees generated each transaction.

Baby Doge Coin

Baby Doge Coin is gaining traction as the community anticipates potential listings on major exchanges like Coinbase and Crypto.com, speculating this could trigger a significant price surge. Fueling the excitement is the coin's impressive trading volume and the ongoing bullish sentiment surrounding meme coins.

$LEASH is the second token in the Shiba Inu Ecosystem. It was originally envisioned to be a rebase token tied to the price of DogeCoin. Later, it was decided that Leash would turn off the rebase function (the keys to allow rebase were burnt to ensure this) and continue as a simple ERC-20 Token.   Though simple, the fact that LEASH’s tokenomics are the polar opposite of SHIB makes it even more intriguing.   SHIB was made to have an enormous supply of (1 quadrillion tokens) with half locked away, whereas the supply of Leash is only 107,647 minted tokens.

Doge Killer

LEASH is trending as community members express frustration and disappointment, with some labeling the project a scam or rug pull. The discussions revolve around the perceived failure of the token, significant price drops, and concerns about funds being extracted from the ecosystem.  However, some community members remain optimistic and highlight the token's limited supply.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Purple Biotech closed down 3.4% on Monday and extended losses in after-hours trading as the company's latest financial results failed to impress the broader market, though retail traders showed some optimism.The company reported a net loss of $0.4 million for the fourth quarter of 2024, significantly narrowing from the $4.9 million loss in the same period a year earlier, primarily due to lower research and development (R&amp;D) expenses.&nbsp;Loss per American depository share (ADS) was $0.20 (basic) and $0.26 (diluted), compared to $3.80 per ADS in Q4 2023, and better than LSEG's mean analyst estimate of a loss of $1.80.CEO Gil Efron highlighted key 2024 milestones, including successful trials for its clinical-stage programs for its cancer therapy candidates <a href="https://stocktwits.com/news-articles/markets/equity/ppbt-stock-surges-on-cancer-drug-cm24-results/cJ9kF29Rh2">CM24</a> and NT219 and advancements in its CAPTN-3 tri-specific platform.&nbsp;The randomized Phase 2 trial for CM24 in second-line pancreatic cancer met all efficacy endpoints, and biomarker data informed a planned Phase 2b study for the second half of 2025.&nbsp;Meanwhile, NT219's dose escalation study determined a recommended Phase 2 dose, enabling a head and neck cancer trial in collaboration with the University of Colorado, expected to begin enrollment in early 2025.Retail sentiment on Stocktwits ended on a bullish note on Monday, but the score was slightly lower than a day ago.&nbsp;<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/PPBT_sentiment_and_message_volume_as_of_March_10_03a40ad961.png" alt="PPBT sentiment and message volume as of March 10.png" width="1316" height="302"><figcaption>PPBT sentiment and message volume as of March 10. | source: Stocktwits</figcaption></figure>Some traders pointed to Purple Biotech's cash runway as a positive factor and speculated that institutional investors may disclose their positions in upcoming 13-F filings, given the strong stock-buying volume observed this year.&nbsp;<stembedurl>https://stocktwits.com/Smittysixty/message/607496322</stembedurl>However, skepticism also lingered. One user questioned the absence of a clear regulatory path for the company's drug candidates, arguing that cost-cutting measures were meaningless without a concrete FDA approval strategy.&nbsp;<stembedurl>https://stocktwits.com/Duediligence20/message/607503439</stembedurl>Others accused management of raising capital to "milk it for salaries."As of Dec. 31, 2024, Purple Biotech had $8.2 million in cash and short-term deposits, which it expects will be sufficient to fund operations into mid-2026.&nbsp;In Q4, the company raised $2.8 million through a registered direct offering and an additional $1.5 million via an open-market sale of 298,000 ADSs at an average price of $3.50.<a href="https://stocktwits.com/symbol/PPBT">Purple Biotech's stock</a> has lost over 45% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Purple Biotech's Shrinking Losses Keep Retail Sentiment In The Green, But Other Pressures Loom

As of Dec. 31, 2024, Purple Biotech had $8.2 million in cash and short-term deposits, which it expects will be sufficient to fund operations into mid-2026.

Equity

WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters.&nbsp;Our focus is on quality, liquid, growth-oriented, and under-followed companies in sectors actively drawing in capital such as AI, blockchain, biotech and consumer.&nbsp;This real-time news surveillance and targeting combined with our proprietary 5-point analysis, aids in uncovering stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.&nbsp;Here’s what we’re keeping our eyes on:<h3>1. Purple Biotech (NASDAQ: PPBT)</h3>Background: Purple Biotech is a clinical-stage oncology company that aims to redefine cancer treatment through its innovative approaches targeting tumor immune evasion and drug resistance. Its lead product, CM24, is a first-in-class anti-CEACAM1 antibody being developed to treat pancreatic and other aggressive cancers. The oncology space, worth billions, continues to see intense investor interest, especially as companies explore biomarker-driven therapies.The News: Purple Biotech unveiled final Phase 2 results showing CM24 combined with nivolumab and chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS) in pancreatic cancer patients with specific biomarkers. The data revealed a 79% reduction in death risk and a 5.1-month OS improvement, particularly in biomarker-enriched patient groups.What It Means: These results not only validate CM24’s potential but also position Purple Biotech to expand its pipeline into broader cancer applications. With a planned Phase 2b trial targeting high-CEACAM1 patients, the company is tapping into precision oncology—a sector that continues to draw investor enthusiasm due to its game-changing potential.Stock Reaction: PPBT skyrocketed 151%, reflecting the market’s recognition of this major milestone in the fight against pancreatic cancer.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_23_40_AM_19763a2e26.png" alt="Screenshot 2024-12-05 at 2.23.40 AM.png">&nbsp;<hr>&nbsp;<h3>2. Stereotaxis (NYSE: STXS)</h3>Background: Stereotaxis is at the forefront of surgical robotics, specializing in robotic magnetic navigation (RMN) systems for minimally invasive endovascular interventions. Its GenesisX system aims to improve precision, safety, and efficiency in procedures, a critical innovation as the global market for robotic-assisted surgeries is projected to grow at a double-digit CAGR over the next decade.The News: The GenesisX robotic system was showcased for the first time at the RSNA 2024 Annual Meeting, in collaboration with Neusoft Medical Systems. The partnership aligns GenesisX with advanced imaging technologies, offering enhanced capabilities for healthcare providers worldwide.What It Means: The exposure at RSNA, one of the largest radiology conferences globally, strengthens Stereotaxis' visibility and positions the GenesisX as a next-generation tool for minimally invasive surgeries. This partnership could unlock new revenue streams as the healthcare sector increasingly adopts robotic solutions.Stock Reaction: STXS edged up 4.18%, with investors optimistic about the long-term implications of the GenesisX system.Stocktwits.com Sentiment &amp; Popularity:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_25_09_AM_6fecf5b145.png" alt="Screenshot 2024-12-05 at 2.25.09 AM.png">&nbsp;<hr>&nbsp;<h3>3. Delcath Systems (NASDAQ: DCTH)</h3>Background: Delcath Systems focuses on innovative therapies for primary and metastatic liver cancers. Its flagship product, HEPZATO KIT™, offers a unique approach to delivering high-dose chemotherapy directly to the liver while minimizing systemic exposure. This precision is critical for targeting liver-dominant diseases—a market that represents tens of thousands of patients annually.The News: The FDA has cleared Delcath’s Phase 2 trial of HEPZATO in liver-dominant metastatic colorectal cancer. The study will compare HEPZATO plus standard chemotherapy with chemotherapy alone, aiming to validate its safety and efficacy in this high-need population.What It Means: HEPZATO has already shown promise in metastatic uveal melanoma, and this expansion could significantly broaden its market reach. The ability to address liver-dominant cancers positions Delcath as a potential leader in a niche but high-value market.Stock Reaction: DCTH rose 6.4% on the day, continuing its strong performance following a 203% year-to-date rally.&nbsp;&nbsp;<hr>&nbsp;<h3>4. BrainStorm Cell Therapeutics (NASDAQ: BCLI)</h3>Background: BrainStorm is a pioneering biotech company developing autologous adult stem cell therapies for neurodegenerative diseases like ALS and progressive MS. Its lead candidate, NurOwn®, is designed to deliver neurotrophic factors directly to damaged neurons, potentially altering the course of these debilitating diseases. With few effective therapies for ALS, the market is ripe for disruptive innovation.The News: BrainStorm announced a December 11 webinar featuring updates on its Phase 3b trial of NurOwn, aimed at refining the therapy’s efficacy for FDA approval. This comes as the company prepares for a pivotal registrational trial.What It Means: If successful, NurOwn could be the first significant breakthrough for ALS in years, addressing an unmet medical need in a multibillion-dollar market. The company’s focus on early-stage ALS patients may improve trial outcomes and strengthen its case for regulatory approval.Stock Reaction: BCLI dipped 2.66%, reflecting cautious investor sentiment as the market awaits trial data.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_26_15_AM_28681ca8de.png" alt="Screenshot 2024-12-05 at 2.26.15 AM.png">&nbsp;<hr>&nbsp;<h3>5. DMG Blockchain Solutions (OTCQB: DMGGF)</h3>Background: DMG Blockchain integrates Bitcoin mining with sustainability and AI-driven data centers. Its Terra Pool initiative is designed to create a carbon-neutral Bitcoin mining ecosystem, catering to ESG-conscious investors and industries. With institutional adoption of Bitcoin accelerating, DMG’s dual focus on growth and environmental responsibility makes it a standout.The News: DMG reported November mining results of 32 BTC, an increased hashrate of 1.66 EH/s, and significant insider purchases by its CEO and COO. The company also secured $17.3 million to fund growth initiatives, including AI and blockchain infrastructure.What It Means: The raised capital and insider purchases signal confidence in DMG’s ability to scale operations and align with Bitcoin’s anticipated market growth. The focus on sustainability could attract institutional players prioritizing ESG compliance.Stock Reaction: DMGI remained stable dipping just slightly, with the market digesting the long-term growth potential from recent investments.&nbsp;<hr>&nbsp;<h3>6. BriaCell Therapeutics (NASDAQ: BCTX)</h3>Background: BriaCell specializes in novel immunotherapies targeting advanced breast cancer. Its lead therapy, Bria-IMT™, is designed to boost the immune system's response against tumors. With metastatic breast cancer affecting over 2 million women globally, there’s an urgent need for effective treatments.The News: BriaCell’s pivotal Phase 3 study of Bria-IMT received a positive safety review from the DSMB, allowing the trial to proceed without changes. The trial is being conducted under the FDA’s Fast Track Designation.What It Means: The DSMB’s approval reinforces Bria-IMT’s safety and paves the way for the company to potentially deliver a game-changing therapy for metastatic breast cancer patients. The Fast Track Designation further emphasizes its potential impact.Stock Reaction: BCTX shares soared 13%, reflecting growing investor confidence in the company’s clinical progress.Rumours from Twitter:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_27_31_AM_e685b0a306.png" alt="Screenshot 2024-12-05 at 2.27.31 AM.png">&nbsp;&nbsp;<h3>7. Laser Photonics Corporation (NASDAQ: LASE)</h3>Background: Laser Photonics Corporation specializes in industrial laser systems, providing innovative solutions for cleaning, material processing, and now pharmaceuticals. With its recent acquisition of Control Micro Systems, Inc., the company is expanding into new sectors, including the fast-growing pharmaceutical and semiconductor industries. The industrial laser market, driven by advances in automation and precision engineering, is projected to exceed $10 billion by 2030, making it a hotbed for innovation.The News: Laser Photonics announced the successful installation of a state-of-the-art pill drilling system at a customer’s facility. The system, a Class I automated CO2 laser with advanced fume extraction and machine vision inspection, is designed to streamline pill production processes. This system also doubles as an anti-counterfeiting solution, addressing critical challenges in the pharmaceutical supply chain.What It Means: This installation signifies Laser Photonics’ pivot into high-demand verticals like pharmaceuticals. By integrating advanced laser technology with automated inspection, the company is positioning itself as a key supplier in a market prioritizing efficiency, precision, and security.Stock Reaction: LASE shares declined 6.40%, reflecting broader market volatility rather than company-specific concerns. Investors appear cautiously optimistic about the company's potential in its newly targeted markets.&nbsp;Also Read:<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/why-this-small-biotech-stock-could-be-primed-for-a-breakout/">&nbsp;Why This Small Biotech Stock Could Be Primed for a Breakout</a>Be the First to Know:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like&nbsp;AST SpaceMobile (NASDAQ: ASTS), which shot up&nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a long or short position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

News Movers: Yesterday’s Hottest News That Could Move the Needle Today

Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks

<a href="https://stocktwits.com/symbol/PPBT">Shares of Purple Biotech</a> (PPBT) surged more than 45% on Monday morning, reaching their highest levels since early October.&nbsp;The Israel-based biopharma reported positive final results from a randomized Phase 2 study of its lead oncology drug, CM24, in patients with pancreatic ductal adenocarcinoma (PDAC).“We are very excited about the final data, demonstrating CM24’s clear and consistent improvement across all efficacy endpoints evaluated in our randomized Phase 2 study,” stated Purple Biotech CEO Gil Efron.&nbsp;He added that the enhanced results in patients with CEACAM1 and other serum markers gave them optimism that selecting a biomarker-enriched patient population could further increase CM24’s efficacy, potentially positioning it as a treatment for multiple CEACAM1-expressing malignancies.The Phase 2 study evaluated CM24, a novel first-in-class anti-CEACAM1 antibody, in combination with Bristol Myers Squibb’s immune checkpoint inhibitor nivolumab and standard-of-care chemotherapy in second-line metastatic PDAC patients. This was compared to chemotherapy alone.<figure class="image"><a href="https://stocktwits.com/symbol/PPBT"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/PPBT_sentiment_and_message_volume_9a32199173.png" alt="PPBT sentiment and message volume.png" width="1314" height="320"></a><figcaption>PPBT sentiment and message volume on Dec 2 as of 10:00 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for PPBT soared to an ‘extremely bullish’ (93/100) score, up from ‘neutral’ just a day ago, accompanied by a surge in message volume.&nbsp;One user optimistically said that PPBT should be trading at $250 per share, 50 times its current price, while another referred to CM24 as “the only pancreatic cancer drug.”<stembedurl>https://stocktwits.com/Duediligence20/message/594680510</stembedurl><stembedurl>https://stocktwits.com/Jpurpleteam/message/594672273</stembedurl>CM24 targets CEACAM1, a multi-functional membrane glycoprotein that plays a critical role in tumor invasiveness, metastasis, and immune evasion.&nbsp;The drug also affects serum neutrophil extracellular trap (NET) levels, which are involved in trapping and neutralizing pathogens.Still, PPBT stock has dropped more than 65% year-to-date.For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-li-xpev-stocks-in-focus-after-record-november/cJ9kNexRhT">Nio, Li Auto, Xpeng Stocks In Focus After China EV Makers Set Monthly Record Deliveries In November</a>

The Israel-based biopharma reported positive final results from a randomized Phase 2 study of its lead oncology drug, CM24, in patients with pancreatic ductal adenocarcinoma.

Purple Biotech Stock Hits Nearly 2-Month High On Cancer Drug Trial Success: Retail Thrilled

CM24 targets CEACAM1, a multi-functional membrane glycoprotein that plays a critical role in tumor invasiveness, metastasis, and immune evasion.

Purple Biotech Reveals Promising CM24 Study Results

Purple Biotech (PPBT) has released an update. Purple Biotech has announced encouraging interim results from their Phase 2 study of CM24 for pancrea...

Purple Biotech Eyes Key 2024 Milestones

Purple Biotech (PPBT) has released an update. Purple Biotech, listed as PPBT on NASDAQ/TASE, has entered a robust phase with multiple clinical data...

Why Purple Biotech (PPBT) Shares Are Trading Lower

Purple Biotech shares are trading lower by 11.5% during Monday's session. The company announced the exercise of warrants for $2 million gross proceeds.
read more...

Purple Biotech (NASDAQ:PPBT) Trading 9.7% Higher

Purple Biotech Ltd. (NASDAQ:PPBT - Get Free Report)'s share price was up 9.7% during trading on Thursday . The company traded as high as $0.67 and last traded at $0.67. Approximately 98,128 shares...

Purple Biotech reports Q4 EPS (19c), consensus (19c)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Purple Biotech convenes a head, neck cancer SAB ahead of NT219 trial

Purple Biotech (NASDAQ:PPBT) Stock Price Up 3.2%

Purple Biotech Ltd. (NASDAQ:PPBT  Get Free Report)s stock price rose 3.2% during mid-day trading on Wednesday . The stock traded as high as $0.82 and last traded at $0.80. Approximately...

Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The oncology pipeline includes CM24, NT219, and CAPTN-3. The CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. The NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.

Purple Biotech Ltd - ADR

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$0.5938
Prev Close	$0.5707
Open	$0.59
Dividend Yield	0.00%
50-Day Moving Average	$1.47
Beta	0.51
Avg. Volume	2.86M
PE Ratio	-0.53

52-Week High	$13.95
52-Week Low	$0.5326
Market Capitalization	$5.36M
EPS (Annual)	-$2.80
Price to Book	0.05
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

PPBT
Purple Biotech Ltd - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest PPBT News

PPBT Purple Biotech Ltd - ADR